Ryman Healthcare stock fell 1.54 percent on October 7

Published on 10/07/2026 at 04:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FY26 operating revenue reached NZD 849.1 million, up 10 percent, while free cash flow turned positive at NZD 188.3 million. Four analysts set a Strong Buy consensus.

RYM, NZRYME0001S4, Illustration mit AI erstellt.

Ryman Healthcare (NZRYME0001S4) stock was trading at NZD 1.76 on the NZX at 2:55 p.m. NZDT on October 7, 2026, down 1.54 percent from the prior close. The share price sits NZD 0.01 above its 52-week low of NZD 1.75 and NZD 1.29 below its 52-week high of NZD 3.05.

FY26 cash flow improved sharply

Ryman's financial reset is built on cash generation rather than revenue alone. Kapitales Research reported that FY26 operating revenue rose 10 percent to NZD 849.1 million, while operating EBITDAF almost doubled to NZD 88.3 million. Free cash flow swung to NZD 188.3 million from an NZD 94.2 million outflow in FY25.

The improvement matters because Ryman operates a development-heavy retirement living model. Its FY26 debt headroom stood at NZD 675 million, gearing was 27.8 percent and the weighted average debt maturity was 4.4 years, according to the same FY27 update from Kapitales Research.

Sales remain the operating test

The first quarter of FY27 produced 325 occupation right agreement sales, comprising 265 resales and 60 new sales. Net resale contracts increased 7 percent from the comparable period, while 414 new-sales units remained available, making inventory reduction a key operational measure.

Ryman also retained FY27 construction expectations of 157 to 168 retirement living units and aged-care beds, with mature aged-care occupancy at 96.1 percent. The company operates integrated retirement villages and care facilities across New Zealand and Australia, according to its investor center.

Consensus target stays above NZD 2.94

Investing.com lists a Strong Buy consensus from four analysts, including three Buy ratings and one Hold rating. The average 12-month price target is NZD 2.94, which lies 67.05 percent above the NZD 1.76 reference price.

That valuation gap places the market's central expectation well above the current quote, but the financial case still depends on converting improved cash flow into durable profitability. A separate review by Simply Wall St said H2 FY26 revenue reached NZD 441.003 million versus NZD 394.013 million in H2 FY25, while the loss narrowed to NZD 126.151 million from NZD 595.749 million.

Ryman Healthcare stock remains near its low

Ryman Healthcare stock was trading at NZD 1.76 on the NZX on October 7, 2026, with volume of 506,764 shares and a market capitalization of NZD 1.8 billion. The next decisive indicators are occupancy, resale volumes and whether the FY26 cash-flow improvement continues through FY27.